Skip to main content

Table 2 Dynamic disease activity indicators and serum MMP-3 during one year follow-up

From: Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study

Disease activity indicators  

1st month

3rd month

6th month

12th month

28TJC, median (IQR)

4 (1 ~ 9)***

2 (0 ~ 4)***

0 (0 ~ 4)***

1 (0 ~ 5)***

28SJC, median (IQR)

2 (0 ~ 4)***

0 (0 ~ 3)***

0 (0 ~ 1)***

0 (0 ~ 1)***

Pain VAS, median (IQR)

2.0 (1.7 ~ 4.0)***

2.0 (0 ~ 3.0)***

1.0 (0 ~ 2.8)***

1.0 (0 ~ 3.0)***

PtGA, median (IQR)

3.0 (3.0 ~ 5.0)***

3.0 (1.0 ~ 4.0)***

2.0 (0.3 ~ 3.0)***

2.0 (0 ~ 3.8)***

PrGA, median (IQR)

3.0 (2.3 ~ 4.0)***

2.0 (1.0 ~ 4.0)***

2.0 (0 ~ 3.0)***

2.0 (0 ~ 3.0)***

HAQ, median (IQR)

0.28 (0 ~ 0.94)***

0.15 (0 ~ 0.50)***

0 (0 ~ 0.25)***

0 (0 ~ 0.46)***

CRP, mg/dl, median (IQR)

0.44 (0.33 ~ 1.19)***

0.33 (0.30 ~ 0.95))***

0.34 (0.18 ~ 0.49)***

0.33 (0.30 ~ 0.89)***

 Normal CRPa, %

54

59

77

70

ESR, mm/h, median (IQR)

34 (18 ~ 48)***

29 (16 ~ 38)***

21 (15 ~ 36)***

26 (13 ~ 42)***

 Norma ESRb, %

27

38

41

39

DAS28c, median (IQR)

3.5 (2.6 ~ 4.4)***

2.7 (2.0 ~ 3.9)***

2.2 (1.5 ~ 3.2)***

2.6 (1.5 ~ 3.3)***

 Remission, %

27

43

53

48

LDA, %

20

20

20

21

 MDA, %

44

30

20

26

HDA, %

9

7

7

5

SDAId, median (IQR)

14.5 (7.6 ~ 24.2)***

8.9 (4.1 ~ 17.5)***

5.3 (1.0 ~ 12.0)***

6.4 (0.3 ~ 12.3)***

 Remission, %

7

18

39

34

 LDA, %

34

41

36

38

 MDA, %

38

30

16

19

 HDA, %

21

11

9

9

CDAIe, median (IQR)

13.7 (7.1 ~ 22.8)***

8.0 (4.0 ~ 15.9)***

4.5 (1.0 ~ 11.5)***

5.5 (0 ~ 11.0)***

 Remission, %

7

18

39

38

 LDA, %

34

45

36

36

 MDA, %

34

26

16

16

 HDA, %

25

11

9

11

Serum MMP-3, ng/ml, median (IQR)

112 (49 ~ 347)

130 (32 ~ 183)

74 (32 ~ 183)*

52 (32 ~ 116)***

 Normal serum MMP-3f, %

32

38

46

62

RF, mg/ml, median (IQR)

119 (39 ~ 252)***

72 (20 ~ 169)***

49 (14 ~ 137)***

78(16 ~ 142)***

Anti-CCP, U/ml, median (IQR)

85 (11 ~ 300)**

53 (13 ~ 296)***

65 (16 ~ 297)**

112(14 ~ 300)*

  1. Pain VAS pain visual analogue scale, 28TJC 28-joint tender joint count, 28SJC 28-joint swollen joint count, PtGA patient global assessment of disease activity, PrGA provider global assessment of disease activity, HAQ health assessment questionnaire, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 Disease Activity Score 28-joint assessment, SDAI simplified disease activity index, CDAI clinical disease activity index, LDA low disease activity, MDA moderate disease activity, HDA high disease activity, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide antibody
  2. *P < 0.05, **P < 0.01, ***P < 0.001. Compared between each time point and baseline by Wilcoxon matched-pairs signed ranks sum test
  3. anormal CRP: <0.5 mg/dl; bnormal ESR: <20 mm/h (female) or <15 mm/h (male); cDAS28-remission: <2.6; DAS28-LDA:2.6 ~ 3.2, DAS28-MDA:3.2 ~ 5.1, DAS28-HDA:>5.1; dSDAI-remission: <3.3; SDAI-LDA: 3.3 ~ 11.0, SDAI-MDA: 11.0 ~ 26.0, SDAI-HDA: >26.0; eCDAI-remission: <2.8; CDAI-LDA: 2.8 ~ 10.0, CDAI-MDA: 10.0 ~ 22.0, CDAI-HDA: >22.0; fnormal serum MMP-3: <60 ng/ml (female) or <120 ng/ml (male)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us